Nicole Lamanna - Concepedia

Author

Nicole Lamanna

Columbia University Irving Medical Center ORCID

Also Known As

Lamanna, Nicole, N Lamanna, N. Lamanna, Nicole Lamanna

378

Publications

8.5K

Citations

H-Index

Concepts

All Affiliations

Columbia University Irving Medical Center Memorial Sloan Kettering Cancer Center The University of Texas MD Anderson Cancer Center Dana-Farber Cancer Institute University of Pennsylvania

About

Nicole Lamanna is an author at Columbia University Irving Medical Center specializing in medicine, pathology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	20	1.6K
2	Health Sciences	6	6	258
3	Cell Biology	1	1	75
4	Cellular Therapies	1	1	75
5	Diagnostic Sciences	1	1	15

Nicole Lamanna

Publications

7.6K

Citations

H-Index

Page 1

	Year	Citations
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia Richard R. Furman, Jeff P. Sharman, Steven Coutré, New England Journal of Medicine	2014	1.7K
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis Anthony R. Mato, Chadhi Nabhan, Meghan C. Thompson, Haematologica	2018	439
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study Anthony R. Mato, Nirav N. Shah, Wojciech Jurczak, The Lancet Phase 1/2Lymphoid NeoplasiaMedicineMalignant Blood DisorderImmunology	2021	432
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia Jennifer R. Brown, Barbara Eichhorst, Peter Hillmen, New England Journal of Medicine	2022	414
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial Jeffrey A. Jones, Anthony R. Mato, William G. Wierda, The Lancet Oncology Hematological MalignancyInterim AnalysisLymphoid NeoplasiaMedicineImmunology	2017	372
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL Ian W. Flinn, Peter Hillmen, Marco Montillo, Blood	2018	331
Outcomes of COVID-19 in patients with CLL: a multicenter international experience Anthony R. Mato, Lindsey E. Roeker, Nicole Lamanna, Blood	2020	316
A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia Susan O’Brien, Nicole Lamanna, Thomas J. Kipps, Blood	2015	239
Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients Anthony R. Mato, Brian T. Hill, Nicole Lamanna, Annals of Oncology Hematological MalignancyLymphoid NeoplasiaOptimal SequencingChronic Lymphocytic LeukemiaMedicine	2017	219
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia Jeff P. Sharman, Steven Coutré, Richard R. Furman, Journal of Clinical Oncology	2019	215

Page 1